http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
| My Groups | biotech-news Main Page | |
Biotech progress overlooked
Rosy report on industry ignores Arizona
http://www.azcentral.com/arizonarepublic/business/articles/0409biz-biotech0409.html
Biotech progress overlooked
Rosy report on industry ignores Arizona
Max Jarman
The Arizona Republic
Apr. 9, 2006 12:00 AM
At 30, America's biotech industry is growing, becoming more stable
and nearing the elusive break-even point.
Since America's first biotech company, Genentech Inc., was formed
April 7, 1976, it has developed into a $50 billion-a-year industry,
with annual revenue growth that has ranged in the past three years
from 16 to 19 percent.
At roughly 5 years old, Arizona's emerging biotech and bioscience
industries show surprising signs of vitality and growth. The number
of Arizona bioscience companies is growing, grant funding is sharply
up and related employment grew 12 percent from 2000 to 2004 to about
72,000 total jobs. advertisement
Work on new drugs drew a record level of grants from the National
Institutes of Health. Grants to researchers in the state rose 30
percent from 2001 to 2004 and now total more than $160 million.
Yet despite the strides Arizona has made toward becoming a major
biotech hub, it remains unmentioned in national reports on biotech.
Accountant Ernst & Young's annual Global Biotechnology Report 2006
makes no mention of the state in its assessment of the country's top
15 biotech areas, which include neighboring states of Colorado and
Utah. The San Francisco Bay area heads the list of locations ranked
by the number of public biotech companies located in the area. New
England and San Diego rounded out the top three with Texas, Colorado
and Utah at the bottom at 13th, 14th and 15th.
Arizona wasn't even mentioned in the "other" category, which
included the states of Hawaii, Minnesota, Missouri, Montana,
Nebraska, Nevada, Oklahoma and South Dakota.
Walter H. Plosila, vice president of the technology partnership
practice for the bioscience and technology consulting firm Battelle,
noted that the Ernst & Young study looks at biotechnology, which is
largely research and testing.
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/messages/
"This is only a narrow slice of the pie that Arizona is pursuing,"
Plosila said. "Arizona is developing its broader bioscience sector,
which also includes drugs and pharmaceuticals, medical devices,
hospitals and labs, and agricultural biotech."
Batelle is the author of the Arizona Bioscience Roadmap, which is
guiding the state's efforts to become a bioscience industry center.
Martin Shultz, chairman of the Arizona Bioscience Roadmap Steering
Committee, noted that Arizona is a relative latecomer to the
bioscience arena and it's not surprising that it has not been
recognized in the Ernst & Young report. The report ranks areas
according to the number of public biotech companies they support,
and so far Arizona doesn't have a critical mass of those types of
companies.
http://www.arizonabiotech.com/
YAHOO! GROUPS LINKS
[EMAIL PROTECTED]
